DIM
XGN icon

DC Investments Management’s Exagen XGN Stock Holding History

DC Investments Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,244
Closed -$221K – 314
2019
Q3 		$221K Buy
+14,244
New +$230K 0.13% 290

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

DC Investments Management's XGN Position: Q4 2019 in Review

DC Investments Management sold out of Exagen (XGN) in Q4 2019, closing a stake of 14,244 shares — an estimated $221K sold.

DC Investments Management first reported a position in XGN in Q3 2019 and held it in 1 quarter. The position peaked at $221K in Q3 2019. 36 funds tracked by Wall St. Rank hold XGN as of Q4 2019.

  • DC Investments Management reported no remaining Exagen position as of Q4 2019 after selling out during the quarter.
  • DC Investments Management sold 14,244 Exagen shares in Q4 2019, an estimated $221K.
  • DC Investments Management first reported a position in Exagen in Q3 2019 and held it in 1 quarter.
  • DC Investments Management's Exagen position peaked at $221K in Q3 2019.
  • 36 funds tracked by Wall St. Rank held Exagen as of Q4 2019.

Based on DC Investments Management's 13F filing for Q4 2019, filed 7 Feb 2020.